Literature DB >> 22316360

The evolution of antiandrogens: MDV3100 comes of age.

Lucy Dumas, Heather Payne, Simon Chowdhury.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22316360     DOI： 10.1586/era.11.210

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  4 in total

1.  Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.

Authors:  Julie N Graff; Charles G Drake; Tomasz M Beer
Journal:  Urology       Date:  2013-02       Impact factor: 2.649

Review 2.  Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.

Authors:  Álvaro Pinto
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

Review 3.  Advances in androgen receptor targeted therapy for prostate cancer.

Authors:  Alia Ahmed; Shadan Ali; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

4.  Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.

Authors:  Shalini Singh Yadav; Jinyi Li; Jennifer A Stockert; James O'Connor; Bryan Herzog; Cordelia Elaiho; Matthew D Galsky; Ashutosh Kumar Tewari; Kamlesh Kumar Yadav
Journal:  Oncotarget       Date:  2016-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.